Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Mallinckrodt
Moodys
Colorcon

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

VUMERITY Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Vumerity patents expire, and what generic alternatives are available?

Vumerity is a drug marketed by Biogen and is included in one NDA. There are three patents protecting this drug.

This drug has forty-three patent family members in twenty-five countries.

The generic ingredient in VUMERITY is diroximel fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diroximel fumarate profile page.

US ANDA Litigation and Generic Entry Outlook for Vumerity

  Start Trial

Vumerity was eligible for patent challenges on December 31st, 1968.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 20th, 2033. This may change due to patent challenges or generic licensing.

Summary for VUMERITY
International Patents:43
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 22
Patent Applications: 28
DailyMed Link:VUMERITY at DailyMed
Drug patent expirations by year for VUMERITY
Generic Entry Opportunity Date for VUMERITY
Generic Entry Date for VUMERITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for VUMERITY
1577222-14-0
2-(2,5-Dioxopyrrolidin-1-yl)ethyl methyl (2E)-but- 2-enedioate
2-(2,5-Dioxopyrrolidin-1-yl)ethyl methyl fumarate
2-Butenedioic acid (2E)-, 1-(2-(2,5-dioxo-1-pyrrolidinyl)ethyl) 4-methyl ester
4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate
ALKS 8700
ALKS-8700
ALKS8700
AS-55046
BCP20867
BIIB098
CHEMBL3989944
CS-0018703
D11154
Diroximel fumarate
Diroximel fumarate (USAN/INN)
Diroximel fumarate [INN]
Diroximel fumarate [USAN:INN]
Diroximel fumarate; ALKS8700; ALKS 8700
Diroximel Fumarete
Diroximel Fumarete(ALKS-8700)
EX-A2876
GTPL10525
HY-100375
K0N0Z40J3W
Q27281786
RDC-5108
RDC5108
SB17410
SCHEMBL15499960
SCHEMBL15511916
TZ001258
UNII-K0N0Z40J3W
ZINC215286156

US Patents and Regulatory Information for VUMERITY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Biogen VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Biogen VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
Harvard Business School
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.